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Abstract
Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject
drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly
driven by injection drug use, with many infected prisoners unaware of their infection status. Risk behaviour for
acquisition of hepatitis C via common use of injecting equipment is widespread in many prison settings.
In custodial settings, effective and efficient prevention models applied in the community are very rarely
implemented. Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange. Thus,
HCV prevention is almost exclusively limited to verbal advice, leaflets and other measures directed to cognitive
behavioural change. Although the outcome of HCV antiviral treatment is comparable to non-substance users and
substance users out of prison, the uptake for antiviral treatment is extremely low.
Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the
impact for the prison system, recommendations regarding hepatitis C prevention, screening and treatment in
prisons have been formulated in this article.
Introduction
Globally, more than 10 million people are held in prisons
and other places of detention at any given time [1]. Due to
the high turnover rate in the prison population, it is
estimated that more than 30 million people spend time in
prisons each year. Drug users in particular often spend
relatively short periods in prisons before returning to their
communities.
Many people held in prisons have severe problems asso-
ciated with drug use, together with related health and
social disadvantages. Those categorised as problematic
drug users constitute a substantial proportion of prison
populations in Europe. Counting only sentenced prisoners
with drug offences as the main offence, 15 of 26 European
countries for which information is available report propor-
tions over 15% [2]. The number of drug users in prisons is
even higher. A systematic review of international studies –
with a preponderance of studies conducted in the United
States – found that 10% to 48% of men and 30% to 60% of
women were dependent on or used illicit drugs in the
month before entering prison [3]. In the European Union,
it has been estimated that about half of all members of the
prison population have used illicit drugs at some time in
their lives [4].
Hepatitis C virus (HCV) infection, which is both preven-
table and treatable, is a major concern in correctional
settings. People who inject drugs (PWID) have high rates
of imprisonment, largely due to the criminalization of
their drug use and to the tendency to fund drug use
through crime. The dynamics of illicit drug use, HCV
infection and imprisonment are closely intertwined [5].
One study found that in Australian prisons, one-third of
entering inmates tested positive for HCV antibodies. The
proportion of positive results among entering inmates
who injected drugs was 56%. Furthermore, one-third of
inmates who were anti-HCV positive were unaware of
their infection status.
In general, 80% of HCV-infected individuals develop
chronic HCV. Of these, 10% to 15% will develop liver
cirrhosis [6]. Three to four percent of patients with
cirrhosis develop hepatocellular carcinoma every year
[7,8]. Worldwide, 25% of liver cancer cases are attributable
to HCV infection [9].
Given the interplay between HCV, drug use and incar-
ceration, HCV has the potential to impose a major disease
burden on European prison populations. The purpose of
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this article is to review evidence and formulate recommen-
dations regarding how to address this situation.
HCV transmission, risk factors and prevention in
prisons
Imprisonment is an independent risk factor for HCV
infection for PWID in the community [10-15]. All modes
of HCV transmission that occur in the community also
occur in prisons. In particular, HBV, HCV and HIV are
transmitted in prisons through the sharing of contami-
nated injecting equipment, and also through unsafe sexual
contact, unsafe skin penetration (such as piercing and tat-
tooing, sharing of razors, and blood-sharing rituals) and
the improper sterilisation or reuse of medical or dental
instruments [16]. Some PWID continue to use drugs such
as opioids, including by injection, while incarcerated, and
some people initiate injecting in prison [17]. In Australian
prisons about half of all imprisoned people who inject
drugs continue to inject drugs in prison [18].
One of the most important risk factors for HCV infec-
tion is intravenous drug use while in prison [12,15]. A
meta-analysis of 30 studies from different countries
showed a clear association between the prevalence of
HCV infection in prisoners and their history of injecting
drug use. There were weaker associations with female
gender and with tattooing. The results showed that HCV
seroprevalence was approximately 11% higher among
already-detained inmates, as opposed to inmates entering
prison. A strong association between HCV infection and
the length of time spent in prison was also seen. These
findings suggest that intra-prison transmission may
contribute considerably to high HCV levels in prison
populations [7].
The prevalence of HCV infection among prison inmates
is many times higher in most custodial settings than in the
general population [19,20], primarily because of the high
proportion of people who inject drugs (PWID) [6] who are
known to be at high risk of infection. Esteban et al
concluded that HCV prevalence in the general population
in Western Europe is 0.5%, and that it is 2.5% and 6% in
Southern Europe and Eastern Europe respectively [21]. A
meta-analysis performed by Vescio et al (2008), showed
that there is a high HCV prevalence in inmates in several
countries around the world. HCV prevalence in inmates
was approximately 30% to 40% (range: 2%–58%) [7].
Different studies from Europe, Australia and the United
States suggest that hepatitis C prevalence rates in prisons
range from 8% to 57% [9,22-24].
In prisoners with a history of injecting drug use, the
global summary prevalence was 64% [25]. Data on HCV
antibody prevalence among injecting drug users in
European prisons between 2005 and 2010 were reported
by five countries, with prevalence ranging from 12% in
Hungary to 91% in Luxembourg [26]. Among female
prisoners the prevalence is two in three. Among female
PWID, the prevalence can be even higher, ranging from
49% to 88% [27].
Patterns of hepatitis C prevalence in custodial settings
include increasing prevalence with age; higher preva-
lence among female prisoners; and increasing prevalence
with multiple admissions to prisons (AIHW 2010).
Infection with more than one strain of HCV may also
be common in prison populations; one study found 24%
prevalence of multiple infections within a cohort of
prisoners who inject drugs [28].
The mortality rate for HCV-induced liver disease in
prisons is high. Chronic liver disease-related deaths
accounted for 16% of deaths among male Texan prisoners
from 1989 to 2003. Either hepatitis B virus (HBV) or HCV
has been identified as a causal factor in more than one-
third of chronic liver disease-related deaths [29].
Health care for prison inmates
Prisoners are entitled, without discrimination, to a stan-
dard of health care equivalent to that available in the out-
side community, including preventive measures. This
principle of equivalence is fundamental to the promotion
of human rights and best health practice within prisons,
and is supported by international guidelines on prison
health and prisoners’ rights, as well as national prison pol-
icy and legislation in many countries [30].
People should not leave custody in a worse condition or
with poorer health than when they entered [18]. The
period of incarceration should be viewed as a public health
window of opportunity, including HCV testing, treatment,
care and support [31]. There is consensus among interna-
tional organisations that all blood-borne virus prevention,
treatment and care interventions that are available in the
community, including harm reduction interventions, must
also be available to prisoners [32-34].
Effective and efficient prevention models that are applied
in the community are very rarely implemented in custodial
settings. Only about 60 out of more than 10,000 prisons
worldwide provide needle exchange [35]. Thus, HCV
prevention is almost exclusively limited to verbal advice,
leaflets and other measures directed toward cognitive
behavioural change. As HCV spreads primarily via inject-
ing drug use in prisons, dependence-driven behaviour can
be expected to predominate [36].
HCV screening in prisons
Many people enter prison with social, medical, and mental
health conditions and re-enter the community with few of
these conditions having been addressed while incarcerated.
Hepatitis C is one such condition, and its management
challenges both the correctional and public health systems.
Identifying all cases of HCV among inmates is an essential
first step, but testing strategies for blood-borne viruses
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and test coverage vary globally between jurisdictions. In
some countries there is no testing procedure at all [37],
while some use voluntary screening and others use a
targeted approach. This situation suggests a need for
ongoing surveillance using a standardized approach to
reliably report prevalence. Ideally, surveillance should
include collection of data on incident cases [5].
Screening for HCV infection and uptake of antiviral
therapy are low in prisons. Uptake for screening ranges
between 9% and 24% [38,39]. In a nationwide survey in
the United States, only one of 36 states reported routine
screening, and only one reported conducting a seropreva-
lence study in custodial care [6]. Of 3,034 new prisoners at
Dartmoor Prison (England), 12% were screened, with 16%
of these found to be seropositive. Seventy-nine percent of
seropositive prisoners with a positive polymerase chain
reaction result were confirmed as cases of positive viremia,
and 27% of these prisoners had a biopsy. Two prisoners
were eligible for treatment [40].
The results of a recent cost-effectiveness study [41] indi-
cated that the introduction of dried blood spot testing
compared to venipuncture for HCV case-finding was likely
to be cost-effective in prisoners in the United Kingdom
and the United States if a minimum level of continuity of
care in treatment or referral between prison and the
community could be ensured.
Qualitative research has described barriers to testing
such as a lack of proactive approaches to offering testing,
prisoners’ fears and lack of knowledge about HCV, low
motivation for testing, and concerns about confidentiality
and stigma, which may mean fewer people are tested
[42,43]. More work is needed to increase the level of test-
ing in prisons.
HCV treatment for prisoners
With good adherence, HCV treatment outcomes for
incarcerated patients who take combination therapy
(peg-interferon and ribavirin) are comparable to those
observed in non-incarcerated patients at similar stages of
disease [44,45]. Studies performed in custodial settings
show acceptable results and sustained viral response
(SVR) rates ranging between 36% and 66% [44-49].
Rates of HCV treatment completion and SVR observed
in correctional populations have been similar to those
reported in community samples [44,49]. The re-infection
rate after successful antiviral treatment in prisons is low
(7%) [50], and is comparable to re-infection rates outside
of prisons. Antiviral treatment in prison also appears to be
cost-effective according to a modelling study that looked
at a US prison population [51].
Several groups have argued that correctional institutions
are an important setting for health interventions such as
screening, diagnosis, prevention, and treatment of HCV
infection [52,53,73]. One of the reasons is that in prison it
is possible to monitor patients more closely, and to
address side-effects and provide psychiatric care as neces-
sary [54]. A second reason is that prisons provide an
opportunity to engage with a difficult-to-reach population
– incarceration may be the first or only time that many
inmates intersect with the healthcare system. A third rea-
son is that medical management and adherence to anti-
viral therapy require lifestyle stability, which can be
provided by incarceration, particularly for offenders with a
history of mental illness or substance abuse [53].
Programmes developed to improve HCV
treatment in prison
In a few studies, intervention programs were developed
or tested to improve the management of hepatitis C in
prisons. Arora S et al developed Project ECHO, a
programme that utilized teleconferencing, videoconferen-
cing, and e-mail communication to connect specialists
with primary care providers in prisons and rural areas in
order to improve access to quality health care for New
Mexicans with hepatitis C. [55]. Through Project ECHO,
226 patients received interferon and ribavirin treatment
for hepatitis C.
In the US state of New York, a programme was created
to provide continuity of HCV treatment to prisoners upon
their release. [56]. A referral process was developed, staff
were mobilized, and health-care facilities in the commu-
nity were recruited to accept referrals. This programme
included 70 prisons and 21 health care facilities. Until
March 2006, 24 inmates were enrolled.
Another treatment programme was developed in
the North Dakota Department of Corrections and Reha-
bilitation. [57]. The treatment protocol followed
National Institutes of Health guidelines for primary
therapy for hepatitis C, with the exception of replacing
weekly pegylated interferon administration with three-
times-weekly consensus interferon administration. The
programme resulted in sustained viral responses of 54%
for genotype 1, 75% for genotypes 2 and 3, and 64%
overall.
Research indicates that nurses play a crucial role in pro-
viding education, support and management of patients
infected with hepatitis C [58-61]. The involvement of
nurses enhances access to treatment, treatment adherence
and response to treatment [58,61,62]. A recent study by
Lloyd et al (Lloyd et al. 2013) evaluated the safety and
effectiveness of a nurse model of care for inmates. In this
study, treatment was initiated in 108 patients (28% of the
291 patients enrolled in the study) and the SVR rate
among patients with complete follow-up data was 69%.
This first prospective treatment programme in a prison
setting demonstrated that the nurse-led model of hepatitis
C care enhanced treatment uptake and reduced the
burden of disease.
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Staff training and support
Staff training and support are important because all people
working in prisons should be aware of blood-borne viruses
and of the universal and special precautions that are
recommended for preventing transmission. Training and
support should be tailored to the needs of different types
of staff working within and outside of health services.
Prison administrators are advised to: [24,63].
• Provide target-group specific peer education and train-
ing on hepatitis and other communicable diseases, routes
of transmission in the workplace (e.g., the risk of needle-
stick injuries occurring during searches of cells), confiden-
tiality, drug use, hepatitis prevention measures, hepatitis
testing and treatment opportunities, drug dependence
treatment, universal precautions and use of protective
equipment, and the rationale for and content of prison
rules and policies related to hepatitis to all prison staff as
part of their initial training, and update this training on a
regular basis during the course of employment.
• Ensure that the training of prison staff addresses
hepatitis-related discrimination and homophobia, reduces
staff opposition to the provision of hepatitis prevention
measures to prisoners, emphasises the importance of
confidentiality and non-disclosure of hepatitis status and
medical information, and promotes the compassionate
treatment of prisoners living with hepatitis. Ensure access
to appropriate post-exposure prophylaxis and counselling.
General recommendations
The following recommendations can be made regarding
hepatitis C prevention, screening and treatment in prisons:
• Close collaboration between prison and public (or
community) health services is needed (e.g. in order to
facilitate community follow-up of treatment; [6,64]. Ensure
continued hepatitis C treatment and care when there is
movement between custodial settings, and when inmates
receiving treatment re-enter the community [7,18,56].
• Incarcerated persons with risk factors for HCV infec-
tion should be screened for viral hepatitis infections [65].
• There is a need to develop approaches to increase the
uptake of testing by raising awareness amongst prisoners
about HCV infection, optimising testing pathways that
support appropriate testing at appropriate times during a
prisoner’s stay in prison, ensuring adequate pre- and post-
test discussion, and developing care pathways for HCV
that enable seamless continuity of care [42]. Proven nurse-
led intervention models could be transferred into the
prison setting in order to guarantee guidance.
• Prisoners should be provided with substance abuse
treatment. Opiate agonist therapy (methadone, buprenor-
phine or diacetylmorhpine) should be administered to opi-
ate-dependent subjects with hepatitis B and C infections
in order to reduce the risks of transmission and re-
infection.
• There is a need to provide sterile injecting equip-
ment and other harm reduction measures to those who
inject while in prison [66,67]. HCV-infected persons
should be counselled on how to avoid transmitting
HCV to others. [68]
• Health education activities (including peer education)
should be carried out, in particular for inmates with no or
minimal prior health education [69,70].
• Depression and psychosis, which are common in
prison settings, occur with interferon treatment. It is
essential to provide psychiatric evaluation of patients prior
to and during treatment, in order to avoid or control the
possible appearance of mental side effects [53,71].
• A multidisciplinary approach through the collabora-
tion of addiction specialists, hepatologists, infectious dis-
ease experts, clinical psychologists, nurses and prison
physicians should be adopted [72].
• If possible, a directly observed treatment (DOT) strat-
egy, which ensures supervision of oral therapy administra-
tion and the injection of subcutaneous therapy by health
care professionals, should be used, as occurs in anti-HIV
and tuberculosis treatment in prison inmates [19].
Conclusion
HCV prevalence is very high in prisons. Intravenous drug
use while in prison is one of the most important risk
factors. The utilization of harm reduction strategies in
order to prevent transmission of HCV in prisons lags far
behind similar efforts taking place outside of prisons. The
scarcity of prison-based needle exchange programmes is a
prominent example of this problem. Although testing for
HCV in prisons should be a cornerstone in the health care
of prison inmates, levels of screening for HCV infection
and uptake of antiviral therapy in prisons are low. Since
HCV treatment outcomes for incarcerated patients are
comparable to those observed in non-incarcerated patient,
programmes to improve HCV treatment in prison, staff
support and recommendations regarding HCV have been
developed and must be implemented. Treatment for HCV
in prison should be routinely available and offered under
standard guidelines and protocols equivalent to those
applied in the community.
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